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The Ca2+-sensing receptor (CaSR) is a class-C G protein-coupled receptor which plays
a pivotal role in calciotropic processes, primarily in regulating parathyroid hormone
secretion to maintain systemic calcium homeostasis. Among its non-calciotropic roles,
where the CaSR sits at the intersection of myriad processes, it has steadily garnered
attention as an oncogene or tumor suppressor in different organs. In maternal breast
tissues the CaSR promotes lactation but in breast cancer it acts as an oncoprotein and
has been shown to drive the pathogenesis of skeletal metastases from breast cancer.
Even though research has made great strides in treating primary breast cancer, there
is an unmet need when it comes to treatment of metastatic breast cancer. This review
focuses on how the CaSR leads to the pathogenesis of breast cancer by contrasting its
role in healthy tissues and tumorigenesis, and by drawing brief parallels with the tissues
where it has been implicated as an oncogene. A class of compounds called calcilytics,
which are CaSR antagonists, have also been surveyed in the instances where they have
been used to target the receptor in cancerous tissues and constitute a proof of principle
for repurposing them. Current clinical therapies for treating bone metastases from breast
cancer are limited to targeting osteoclasts and a deeper understanding of the CaSR
signaling nexus in this context can bolster them or lead to novel therapeutic interventions.
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INTRODUCTION: THE CALCIUM SENSING RECEPTOR
The concept that extracellular Ca2+ acts directly on parathyroid cells to regulate PTH secretion
had been afloat since the 1960’s (1, 2). However, the first precise assertion of the hypothesis
suggesting a “possible existence of a divalent cation receptor” on the cellular surface came from
electrophysiological experiments performed in rat parathyroid cells in 1983 (3). The concept of a
calcium receptor gained traction in the 1980’s, and by 1990 several characteristics had been revealed.
In 1991, two independent groups (4, 5) showed a viable strategy for cloning the calcium receptor
in Xenopus oocytes, an approach later used by Ed Brown et al. in cloning the cDNA encoding the
bovine parathyroid calcium receptor (6). The irrefutable evidence on the existence of the receptor
in 1993 was further reinforced by the clinically significant discovery that mutations in the calcium
sensing receptor gene gave rise to inherited disorders of disrupted calcium homeostasis (7).
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The extracellular CaSR is a dimeric class-C G protein-coupled
receptor (GPCR), closely related to metabotropic glutamate
receptors, gamma-aminobutyric acid type B (GABAB) receptors,
various taste receptors and pheromone receptors. The human
CaSR is a 1,078 amino acid protein, with a large 612 amino acid
extracellular domain making up two lobes which adopt a Venus
flytrap (VFT) conformation (8). Upon agonist stimulation, an
open cleft of the VFT closes in, which is believed to induce
conformational changes in the other domains, initiating signal
transduction (9). Although the nomenclature points toward the
main ligand of this receptor (Ca2+ ion), it does little to disclose
its promiscuity of responding to various di- and trivalent cations,
basic polypeptides, amyloid β-peptides and some aminoglycoside
antibiotics (10–14). These constitute orthosteric agonists or type
I calcimimetics which stimulate the receptor in the absence of
Ca2+ or increases the sensitivity to calcium, albeit with different
potencies. The second type of CaSR agonists are called allosteric
modulators. These generally bind to a site different from that
of orthosteric agonists, affecting the signaling and affinity of
the orthosteric agonists either positively (calcimimetics) or
negatively (calcilytics).
Signaling through the CaSR is multifaceted. Based on the
majority of studies of this receptor in parathyroids, it has
been shown to mainly interact with Gq/G11 heterotrimeric
G protein (15, 16). Various intracellular cascades finally lead
to a decrease in the secretion of parathyroid hormone (PTH)
and a reduction in renal tubular Ca2+ reabsorption (17).
Intracellular Ca2+ kinetics has been reported to be influenced
by G12/13 pathways in different cell types. An example of such
a modulation has been reported in the bone, where a G12/13
mediated activation promoted osteoblastic differentiation and
downregulated osteoclastogenesis (18, 19). Also, since G12/13
signaling has been implicated in cell migration, it has been
hypothesized to aid metastatic spread of breast and prostate
tumors (20–22). CaSR mediated Gs signaling has been observed
in pituitary cells and has been shown to affect human fetal
lung development (23, 24). Being a multimodal chemosensor
involved in transducing extracellular metabolic signals, the CaSR
is also involved in preferential activation of distinct intracellular
pathways in a phenomenon termed as “biased signaling” or
“stimulus bias” (25). This is being leveraged in contemporary
strategies for drugs targeting GPCRs (including the CaSR) while
minimizing side-effects (26, 27). The alternation in coupling
of G-proteins between normal and transformed breast cells
was first hypothesized by Mamillapalli et al. and we have
summarized it separately in our review as this is an important
facet. This section aims to provide an opportunity to appreciate
the various evidences of multiple G-protein couplings of this
GPCR without deep-diving into the details of the downstream
signaling pathways. For a comprehensive discourse on signaling,
one can refer to an excellent review by Conigrave et al. (25).
The CaSR senses minor perturbations in serum Ca2+ levels
and thus maintains an equilibrium by tightly regulating PTH
secretion, renal calcium control, and bone remodeling. When
the CaSR senses a dip in the extracellular Ca2+ concentration,
it induces PTH secretion from the parathyroid glands. The
secreted PTH acts by reducing kidney Ca2+ excretion, increasing
intestinal Ca2+ absorption, and increasing bone resorption to
release skeletal Ca2+. On the other hand, an increase in the
physiological Ca2+ level causes receptor activation and inhibition
in PTH synthesis and secretion (28). As already mentioned,
the physiological significance became apparent when various
inherited disorders like familial hypocalciuric hypercalcemia
(FHH) and neonatal severe hyperparathyroidism (NSHPT) were
found to be caused by loss-of-function mutations in the CaSR
gene (7). Alternatively, gain-of-function mutations were found
to give rise to autosomal dominant hypocalcemia (ADH) and
Bartter Syndrome type V (29, 30). However, the receptor
is not restricted to calcium homeostasis but also has been
implicated in diverse processes like cellular proliferation, cellular
differentiation, secretion, and gene expression in different tissues
such as stomach, intestines, skin, brain, liver, and heart (31–39).
Before delving into a rationale for targeting this versatile receptor
in breast cancer, we will briefly look into its function in the
mammary gland and how it plays a role in cancer progression.
CASR IN THE NORMAL MAMMARY
FUNCTION
The first report of localization and confirmation of expression
of CaSR in human breast tissues was published by Dr. Edward
M. Brown’s laboratory (40). They observed the expression of
both mRNA and protein levels in ductal epithelial cells which
was further confirmed by successive findings in mice (41).
Immunofluorescence staining of lactating glands revealed the
expression of the receptor in luminal epithelial cells at the
basolateral surface and in the cytoplasm (41, 42). Although it
is reasonable to surmise that the CaSR is mainly located on
epithelial cells in the breast, these studies do not exclude minimal
presence of the receptor in stromal cells (43). The role of the
receptor was elucidated to be involved in controlling lactation
by modulating the production of PTHrP and regulating calcium
(41). The expression of CaSR in mammary epithelial cells was
subsequently shown to be upregulated during lactation and
downregulated during pregnancy (41). To circumvent neonatal
deaths from a homozygous CaSR gene disruption, the CaSR
gene was disrupted in mammary epithelial cells in mice at the
onset of lactation which resulted in altered maternal calcium
homeostasis (44). This genetic ablation had a domino effect- the
lactating mothers were hypercalcemic, showed decreased PTH
secretion (with increased renal excretion of calcium), increased
secretion of PTHrP intomilk, and reduced calcium transport into
the milk (44). The suckling neonates demonstrated decreased
calcium accumulation, evident from their ash calcium content
(44). Although the lactating breast coordinates maternal and
neonatal calcium homeostasis, it can be concluded from studies
till date that the CaSR does not play a pivotal role in the
development or differentiation in the normal mammary gland.
The caveat of this conclusion is that most studies have focused
on the period of lactation where there is the highest expression of
CaSR (42).
Culmination of intensive work at understanding the
pathophysiology of humoral hypercalcemia of malignancy
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(HHM) led to the discovery of the parathyroid hormone-related
protein (PTHrP) (45). Owing to the N-terminal homology of
PTH and PTHrP, both interacts with the same GPCR termed
as type 1 PTH/PTHrP receptor (PTH1R). Unlike PTH which
functions like a peptide hormone, PTHrP does not circulate
(except during lactation and cancer) (46). In Pthlh−/− and
Pth1r−/− embryos, loss of PTHrP signaling led to arrested
mammary and nipple morphogenesis; while the overexpression
of PTHrP (via the keratin 14 promoter) gave rise to ectopic
nipples (45–47). A classic endocrine negative feedback loop is set
up by CaSR signaling in the lactating breast which suppresses
PTHrP production to counter bone calcium resorption, which
has been proved both genetically and pharmacologically (41, 48).
CASR IN BREAST CANCER
The CaSR seems to function as an oncogene or tumor suppressor
gene based on the cancer site (Figure 1). The expression of CaSR
is greatly reduced or nullified in neuroblastomas, parathyroid
FIGURE 1 | The role of CaSR in cancer.
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cancer, and colorectal cancer (49–51). In our tissue of interest,
the mammary gland, most of the evidences point toward its role
in promoting cancer progression. Besides this, the CaSR also acts
as an oncogene in several cancers such as ovarian, prostate, and
testicular cancer (52–54). Although we will be focusing on the
mammary gland, it is important to keep inmind the tissues where
the CaSR aids tumor progression; cumulative evidences of similar
function in different tissues would help us decipher the intricacies
of the signaling aspects of the CaSR.
Genetic Aspects of the CaSR
Studies have aimed to find a correlation between breast cancer
risk and single nucleotide polymorphisms (SNPs) of the CaSR
gene. According to a recent review, only four articles (comprising
of case-control and meta-analyzes studies) point toward a
significant association (55). The African-American Breast Cancer
Epidemiology and Risk (AMBER) study demonstrated that the
SNP in CASR rs112594756 presented with a higher odds ratio
for estrogen receptor status in breast cancer (56). Li et al. found
that the SNP rs17251221 was associated with reduced mRNA and
protein levels of CaSR and could be a risk factor as well as a
prognostic indicator of breast cancer. It is noteworthy that the
same intronic polymorphism with “AG” and “GG” genotypes
lowered the risk for ovarian cancer, even if it didn’t correlate
with survival (57, 58). CaSR SNP at rs1801725 was shown to have
associated breast cancer with circulating calcium levels. Wang L.
et al. showed that the decreased sensitivity of the CaSR to calcium
due to the aforementioned polymorphism might predispose
risk of breast cancer in up to 20% of cases with aggressive
breast tumors linked to calcium in circulation (59). BRCA1 is
a well-characterized tumor-suppressor gene, which is involved
in various cellular functions and women who carry a mutated
BRCA1 allele are at higher risk of developing breast cancer.
Functional linkage studies between the CaSR and BRCA1 showed
that cells harboring BRCA1 mutants with loss of expression of
BRCA1 had downregulated CaSR expression. Data from these
studies also showed that BRCA1 functioned through the CaSR
in inhibiting survivin (an anti-apoptotic factor) expression. This
means that the CaSR could rescue, in part, the deleterious effect
of loss in BRCA1 function (60).
PTHrP-CaSR Axis
We already discussed the role of PTHrP in the normal
functioning of the breast, but it becomes interesting how
it interacts with the CaSR in contributing to pathogenesis.
Some excellent research by the Wysolmerski lab led to a
possible explanation of the opposing effects of CaSR on PTHrP
production based on alternate G-protein coupling. Generally,
PTHrP secretion is suppressed by rising calcium levels in the
normal breast tissue, but it is stimulated in breast cancer cells.
It was seen that the CaSR used the Gαi coupling in normal
mammary epithelial cells but switched to Gαs in MCF-7 and
Comma-D cells. The alternative coupling stimulated adenyl
cyclase activity (as opposed to inhibition in non-transformed
cells), resulting in activation of cAMP/PKA pathways which are
known to regulate PTHrP gene expression and PTHrP secretion
(61). Manipulating the cAMP levels independent from CaSR
activity was seen to produce a similar effect in PTHrP production
in the mentioned cell types (62). Activation the CaSR can also act
in a concerted way with transforming growth factor β to promote
PTHrP secretion, as seen in MCF-7 and MDA-MB-231 cells (48).
PTHrP was discovered to be a causal factor in HHM but has
been subjected to conflicting reports in its function in primary
tumors. While some reports suggest that PTHrP production
by primary breast tumors is a marker of bone metastases,
others, notably a large prospective study, suggested that PTHrP
production by the primary tumor confers a “less invasive
phenotype” and inversely correlates with bone metastases (63,
64). The PTHrP gene, on the other hand, was recently identified
as a genomic locus for breast cancer susceptibility (65). However,
efforts aimed at deciphering the relation between CaSR and
PTHrP in breast cancer demonstrated that the action of CaSR
is mediated by nuclear PTHrP and partly affects proliferation
and apoptosis. When a mutant form of PTHrP which couldn’t
translocate into the nucleus was transduced into cells, they failed
to rescue the phenotype affected by depletion of the CaSR.
When either the CaSR or PTHrP was knocked down in BT474
and MDA-MB-231 cells in vitro, it sensitized them to cellular
death in response to increasing concentrations extracellular
calcium. Furthermore, ablating the CaSR in MMTV-PyMT
(mouse mammary tumor virus-polyoma middle tumor-antigen)
transgenic mouse model tumor cells promoted apoptosis and
inhibited growth ex vivo (66). Mice bearing C26-DCT colon
tumors treated with Cinacalcet to reduce hypercalcemia presents
an interesting case as the tumor cells do not express the CaSR.
The attenuation in PTHrP-mediated increase in serum Ca2+, as
observed in parathyroidectomized rats in which hypercalcemia
had been induced with PTHrP injections, resulted from increased
secretion of calcitonin and suggests calcimimetics didn’t act
directly on the tumor cells (67, 68).
BONE METASTASIS
Following Paget’s seed and soil hypothesis, the bone
microenvironment provides a fertile “soil” for breast and
prostate cancer “seeding,” among other carcinomas, by hosting
a plethora of biochemical or physical properties that makes it
attractive for tumor growth (69, 70). This metastatic niche also
provides homing signals like pH and extracellular Ca2+, which
can be said to lure the cancer cells. Our team showed that highly
bone-metastatic cells were prone to a greater migratory effect
compared to less metastatic ones in response to Ca2+ and siRNA
directed against the CaSR was able to mitigate that effect (71).
Taking that hypothesis forward, we were also able to show in vivo
that overexpression of a functional CaSR in MDA-MB-231 cells
greatly increased their osteolytic potential mediated by epiregulin
secretion, and downregulation of OPG (Osteoprotegerin) in
osteoblastic cells, which could upregulate osteoclastogenesis (72).
As adhesion also plays a key role in metastasis, Tharmalingam
et al. reported for the first time that the coupling of CaSR and
integrins in rat medullary thyroid carcinoma cells, along with
release of [Ca2+]i, promotes adhesion and migration (73).
This builds upon the studies which have shown that CaSR aids
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metastasis and hematopoietic stem cell harboring in adult bone
marrow- which are also dependent on integrin-mediated cell
adhesion (74, 75).
Before cancer cells find their way into the circulation, they
may have to adopt an invasive phenotype, a phenomenon
referred to as the epithelial–mesenchymal transition (EMT).
During this adoption, an overlooked feature of breast tumors is
the biological significance of microcalcifications in situ, mainly
comprising of calcium oxalate or hydroxyapatite (76, 77). This
had been partly explored long back, where the osteotropism
of breast cancer was correlated with its ability of inducing
microcalcifications by expressing bone matrix proteins (78).
Clinically, mammographic calcifications aid in distinguishing
benign from potentially malignant changes (79). Although
calcium oxalate is mostly associated with benign tumors,
hydroxyapatite has been linked to both benign and malignant
ones (80). Taken together, it points toward a significant role
of calcium signaling. Davis et al. found that the EGF-induced
EMT in MDA-MB-468 cells was calcium signal dependent (81).
Activation of the CaSR in breast cancer cells have also been
shown to stimulate cell proliferation acting through membrane
metalloproteinases, upregulating the transient receptor potential
channel 1, stimulating EGFR, and ERK1/2 phosphorylation (82,
83). The link between CaSR and EMT in breast cancer is yet
to be explored, but studies have shown that inducing CaSR
in colon cancer (where it acts as a tumor-suppressor) inhibits
EMT and lower expression in lung adenocarcinomas promotes
a mesenchymal phenotype (84–86). The estrogen receptor alpha
(ER) expression in primary breast cancers is linked to incidence
of bone metastases and its activity is a clinically important
metric (87). It was reported that high Ca2+ levels which are
released during tumor induced bone resorption, and specific
CaSR agonists increases ER transcriptional activity and decreases
ER protein levels (88). Although there is a need for confirming
an unequivocal role of the CaSR in bone metastasis, we can still
speculate the mechanisms by which the bone microenvironment
might act through the CaSR in promoting osteolysis or bone
metastases. The tumor cells needs to adapt to this Ca2+ rich
microenvironment to proliferate and promote osteolysis, and
increased PTHrP secretion might be contributing to this by
its paracrine actions (61). Bone marrow stromal cells and
osteoblasts express the PTH1R which binds to PTHrP produced
by skeletal metastatic breast cancer cells initiating the vicious
cycle and is exacerbated by the calcium-CaSR signaling. Of all the
factors released during bone resorption, matrix-derived growth
factors can aid tumor cell survival and/or PTHrP production
(43), feeding the cycle of osteolysis and thus, investigating the
CaSR-PTHrP axis might open doors on a therapeutic front. If
metastatic cell growth can be halted, the tumor-bone vicious
cycle can be targeted, and the bone microenvironment can be
rendered inhospitable for tumor colonization- it can be the ideal
therapeutic option, which makes targeting the PTHrP-CaSR axis
seems so compelling.
In the “vicious cycle” fueled by tumor cells that leads to a
disrupted osteoblast-osteoclast coupling, the CaSRmay also serve
as a target on osteoclasts. It was shown that by either antagonizing
the receptor on osteoclasts or in those lacking a functional CaSR
led to increased apoptosis induced by high extracellular Ca2+ and
also impaired osteoclastogenesis. Their data also suggested that
CaSR mediated NF-κB translocation to the nucleus of osteoclasts
and their activation led to apoptosis of mature osteoclasts (89).
Identifying the interplay between the CaSR and various factors
which aid tumor cell homing, survival and proliferation in the
bonemicroenvironment can shed light on the extent it is involved
in the processes.
CALCILYTICS AND MODE OF ACTION
The definition of “calcilytics” is based on its function and doesn’t
account for its structure or CaSR-binding sites. The rationale for
developing such compounds stemmed from the requirement of
alternative small molecule calcilytics for treating osteoporosis;
the standard of care at that time being anabolic therapies using
PTH analogs (teriparatide) and PTH-related peptides (90). In
2001, the compound labeled as NPS-2143 became the first one to
be reported in having the ability to inhibit CaSR activity (91, 92).
Its potency was apparent, having an IC50 of 43nM in blocking
Ca2+ accumulation in response to receptor activation (carried
out in HEK 293 cells), going as high as 3µM without affecting
several other structurally similar GPCRs. Intravenous infusions
in normal rats caused a rapid 4- to 5- fold increase in circulating
PTH levels, and plasma Ca2+ levels were significantly elevated
only after 90min into the infusion with a slow return to baseline
levels. Pharmacokinetic studies revealed an oral bioavailability of
11% in rats and high rate of clearance attesting to its low t1/2 of
2 h. Additionally, a single oral dose led to a sustained increase
(>4 h) in plasma PTH levels, owing to its lipophilic nature which
possibly causes prolonged systemic exposure (91, 92).
Despite harboring promise, calcilytics failed in treating
osteoporosis in clinical settings; it has been well-reviewed but we
will summarize the findings (93). Three calcilytic compounds,
namely ronacaleret, JTT-305/MK-5442, and AXT914, were able
to advance into Phase II clinical trials but halted due to lack
of efficacy at pre-specified interim analyses. However, they were
well-tolerated and had no off-target effects that staked their
safety/efficacy (92, 93). Their failure due to on-target effects on
bone is because administering calcilytics is equivalent to ablating
the CaSR and blocking the CaSR in bone cells has been shown
to influence bone turnover (93–95). There have been many
studies to show the essential role of the CaSR in osteoblast
differentiation, survival, and proliferation (96). In osteoclasts,
calcilytics have a different pharmacological profile, as compared
to parathyroid cells, which can be due to decreasing pH in the
resorption pits which makes the CaSR less responsive (96–98).
Calcilytics and Cancer
We previously stated that the CaSR acts as an oncogene in the
prostrate, ovarian, and testicular cancer. In addition, Brenner lab
showed that the bone metastasis caused by renal cell carcinoma
(RCC) was promoted by the extracellular Ca2+ through the
CaSR. They found that the CaSR was highly expressed in patient
samples from those with bone metastases as compared to those
with no or lung metastases. The calcilytic NPS-2143 acted in a
predictable manner by blunting the response to calcium induced
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migration and proliferation of bone metastatic primary RCC
cells (99). Very recently, their lab also implicated the receptor
in promoting bone metastases in mice, using 786-O (RCC) cells
with stably transfected CaSR gene. NPS-2143 was able to inhibit
the phosphorylation of SHC, AKT, ERK, JNK and p90RSK in
response to high Ca2+ in these transfected cells (100).
An overlooked aspect of the targeting CaSR is its interplay
with cytokines and growth factors, which is quite interesting
given that they play a significant role in cancer. Nielsen et al.
were probably the first ones who demonstrated the positive
correlation between the cytokine IL-1β and CaSR mRNA levels
in bovine parathyroid gland samples. They were investigating
the paracrine nature of IL-1 on PTH secretion, PTH mRNA,
and CaSR mRNA; IL-1β (2,000 pg/ml) upregulated CaSR
mRNA levels by 180% (of control) and an IL-1 receptor
antagonist abolished this effect (101). The first direct evidence
of the involvement of the endogenously expressed CaSR in
the secretion of multiple cytokines and growth factors by
metastatic breast cancer cells was reported by Hernández-
Bedolla et al. They reported that CaSR activation in MDA-
MB-231 cells transactivated EGFR and stimulated the secretion
of endothelial chemotactic and pro-angiogenic factors like
GM-CSF (granulocyte-macrophage colony stimulating factor),
EGF (epidermal growth factor), MDC (macrophage-derived
chemokine), FGF-4 (fibroblast growth factor-4), and IGFBP-
2 (insulin-like growth factor-binding protein-2). The receptor
was also shown to diminish the constitutive secretion IL-6 and
β-NGF (β-nerve growth factor). It was interesting to see that
common angiogenic factors (like Vascular endothelial growth
factor) and pro-inflammatory cytokines (like TNF-a, IL-1a, IL-
10, and others) were not detectable in response to PAE (porcine
aortic endothelial) cells in the microarrays used for screening,
implying that the CaSR is selectively responsible for promoting a
specific set of growth factors and cytokines. As anticipated, NPS-
2143 antagonized the receptor response, inhibited the secretion
of the mentioned factors, and attenuated the angiogenic effect
of the breast cancer cells on PAE cells (102). An apparent
paradox regarding the secretory patterns of IL-6 was addressed
later by the same lab. They observed that basal activity of
the endogenously expressed receptor in MDA-MB-231 cells
stimulated IL-6 secretion, but agonist stimulation seemingly
had an opposite effect. Agonist stimulation, with 1.85mM
Ca2+ and R568 (a calcimimetic), engages the CaSR in Rab11a
dependent endosomal recycling and PI3K signaling pathway,
crucial in inhibiting IL-6 secretion. To compare it with “normal”
mammary epithelial MCF-12A cells, CaSR stimulation increased
IL-6 secretion. Regardless of cell type and receptor activation, the
calcilytic NPS-2143 decreased detectable IL-6 levels in the cell
culture supernatants (103). The estrogen receptor (ER) activity
induced by high calcium levels in ER+ breast cancer cells were
also evidenced to be partly rescued with calcilytics (88). A
recent report on the CaSR promoting gastric cancer progression
mentions a few experiments where they used calcilytics in vivo
to bring down tumor growth and metastasis. Mice bearing
xenografted tumors injected with CaCl2 or CaCl2 plus NPS-2143
at the site of implantation had around 46% reduction in tumor
volume with the treatment. Also, MKN45 cells pre-cocultured
with or without NPS-2143 had a significantly lesser number
of metastatic tumors when injected intraperitoneally in nude
mice (104). This is quite intriguing as it is the first time to
our knowledge where calcilytics have been used in vivo, albeit
intratumorally, to directly target tumors where CaSR aids cancer
progression. The team went on to show that there is a functional
link between CaSR and human telomerase reverse transcriptase
(hTERT) in gastric cancers, where calcilytics inhibited Ca-
mediated upregulation of hTERT and accumulation of p-Akt
(105). Amore direct effect of calcilytics on gastric cancer cells was
also reported, where NPS-2143 inhibited migration, invasion,
proliferation, and promoted apoptosis. They also reported the
upregulation of CaSR in gastric cancer cells and tissues (106).
A short communication from Yamamura et al. showed that the
calcilytic NPS-2143 inhibited the proliferation and migration in
prostate cancer cells, suggesting their therapeutic potential (107).
In all these types of cancer where the CaSR is upregulated or acts
as an oncogene, like in breast cancer, the effect of calcilytics in
impeding metastasis is highlighted.
Every therapeutic decision involves a risk-benefit tradeoff.
The CaSR might be therapeutically challenging to target due to
its ubiquity and its role in maintaining physiological functions.
Systemic administration of calcilytics may result in unpredictable
effects in a complex disease like breast cancer. The main risk
would be exacerbating existing hypercalcemia as data amassed
from the various clinical trials with calcilytics showed pre-dose
serum Ca2+ to be elevated in many cases (93). If calcilytics are
suggested as a therapy, it would be important to diagnose if the
patient has hypercalcemia and whether it arose from HHM with
osseous involvement, or hyperparathyroidism from adenomas
(108) because calcilytics would be detrimental in the latter case.
Besides this, clinical trials attest that calcilytics were devoid of any
other major side-effects (90).
Calcilytics were developed to treat osteoporosis by a bone-
anabolic effect and mimics an intermittent PTH treatment.
Continual exposure to PTH has been shown to have catabolic
effect but intermittent administration of PTH or PTHrP results
in net bone formation (109–111). Swami et al. showed that
this effect of intermittent PTH treatment reduced cancer
cell engraftment and incidence of skeletal tumors in vivo in
various models involving MDA-MB-231 cells or 4T1 murine
human breast cancer tumors, and that it rendered a less
metastatic phenotype to the cells. However, pre-treatment of
mice with intermittent PTH in an orthotopic 4T1 breast cancer
model didn’t affect the primary tumor volume. In other pre-
treatment or treatment models, the treatment reduced skeletal
metastases but didn’t affect metastases to other internal organs
(112). This effect of intermittent PTH treatment on the bone
microenvironment to hinder metastases to bones can also be a
mechanism through which calcilytics could function in reducing
tumor burden. Whether or not calcilytics are able to release
the desired amount of PTH to reach the aforementioned effect
require further investigation. The lack of tissue selectivity of
calcilytics is still a challenge and it needs further development
to prevent off-target effects or on-target effects in the bone,
but it is interesting that it can probably infiltrate the bone
microenvironment. However, when coupled to 17β-estradiol in
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FIGURE 2 | The vicious cycle of osteolytic metastasis in breast cancer and therapeutic targets: tumor cells produce PTHrP which acts on osteoblasts (Ob) to
stimulate production of RANKL. When RANKL binds to its receptor RANK, osteoclast precursor cells undergo differentiation to activated osteoclasts (Oc). These
activated Oc now undergo maturation and start active resorption which releases copious amount of Ca2+ and growth factors. Acting via the CaSR on the tumor cells,
Ca2+ is considered to be a chemoattractant and also further stimulates PTHrP synthesis, thereby aggravating the vicious cycle. Clinically, the standard of care is either
RANKL inhibitors like denosumab which binds to it and prevents it from interacting with its receptor RANK or bisphosphonates which are metabolic poisons taken up
by the osteoclasts during resorption. Anabolic therapies, like intermittent teriparatide or the intermittent PTH effect mimicked by administering calcilytics, can be a
promising option as they would increase Ob activity. Calcilytics, which are CaSR antagonists, can also aid by decreasing the chemoattraction of the tumor cells to the
Ca2+ gradient and by hindering PTHrP production.
ovariectomized rats, it led to increase in cancellous bone area
(97), which opens up an interesting possibility of coupling anti-
resorptives and calcilytics.
THERAPEUTIC PERSPECTIVE
The principal therapeutic strategies in the market aim at
targeting osteoclasts, given that most bone metastases intersect
with exacerbated osteoclast activity (Figure 2). Under the broad
umbrella of antiresorptive therapies, one major category is a
class of compounds called bisphosphonates, which in essence are
metabolic poisons inducing apoptosis in osteoclasts. The prodigal
drug of this class appears to be zolendronate, which has braved
various clinical trials to show its effectiveness in reducing skeletal
related events (SREs) and also shown to have anticancer activity
when used as an adjuvant or neoadjuvant (113). Unfortunately,
this therapy comes with its share of side-effects like osteonecrosis
of the jaw, bone pain, hypocalcemia, and fractures. Also their
high affinity for the bone makes them build up in the tissues
and causes adynamic bones (114, 115). Another major category
is the humanized anti-RANKL antibody, denosumab, which
acts by blocking the association of RANK-RANKL and in
turn blocks osteoclastogenesis. Denosumab appears to be the
preferred anti-resorptive therapy in the market as phase III
clinical trials showed that they are more effective in delaying
SREs compared to zolendronate (116). Side-effects of this therapy
include hypocalcemia, nausea, fatigue, and osteonecrosis of the
jaw (116, 117). Both these therapies have also highlighted their
role in antitumoral effects by aiding the antitumor immune
system (118, 119). In patients with osteolytic bone diseases who
are put on such therapies, the disease often progresses and in
50% of the patients there is a recurrence with SREs (120). Recent
alternative therapies for targeting osteoclasts include Cathepsin-
K inhibitors, c-src inhibitors, and integrin inhibitors (121–123).
Some cathepsin-K inhibitors made their way to clinical trials but
had to be discontinued due their side effects on skin, risk of
atrial fibrillation, and stroke. There are ongoing trials with c-src
inhibitors like Dasatinib and Saracatinib, and also with anti-αvβ3
integrin MABs (Etaracizumab) (113, 115).
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Since metastatic cancer cells are unable to destroy the bone on
their own, they hijack the bone cells to create an environment
favorable for their growth leading to the dire complications
associated with bone metastases. Thus, it is quite understandable
why most of the drugs in the market for bone metastatic patients
are bone targeted. An interesting proposition about harnessing
osteoblasts, based on data from patients, in vivo experiments,
and co cultures, suggest that osteoblasts and their secretomes
were hostile to growth of myeloma cells in the bone (124, 125).
Similar in vitro data in the case of breast cancer also showed
that introduction of osteoblasts curbed bone turnover caused
by osteolytic breast cancer (126). Although other therapies have
been tackling cancer related bone diseases, regaining bone health
and quality remains a challenge. It wouldn’t be far-fetched to talk
about bone anabolic agents in such cases. The most widely used
anabolic agent is teriparatide (PTH 1-34) for osteoporosis and
was shown to suppress myeloma growth. The use of teriparatide
in the clinic on patients with cancer is highly improbable as it
was shown to increase incidences of osteosarcoma in rodents-
but the anti-tumor effects of PTH warrants further investigation
into the use of bone anabolic agents against osteolytic breast
cancer. Calcilytics can be a strong contender as there is mounting
evidence toward its inhibitory effects on metastasis of cancer
cells as discussed and that it has a bone anabolic effect. The
risk of using such compounds are that it may exacerbate
the hypercalcemia, and by blocking renal excretion of Ca2+,
further raise serum Ca2+ levels. Research on calcilytics for such
indications should be aimed at increasing its tissue specificity,
reducing off-target effects, targeted delivery, and finding out its
interaction with current therapies in the market. A drug with
direct actions on tumor cells and having a potent anabolic effect
might be quite helpful in the clinic.
CONCLUSION
Since the discovery and cloning of the extracellular CaSR, we have
been able to throw light on its vital role in orchestrating calcium
homeostasis in the body. However, among its non-calciotropic
roles, it has been shown to be expressed in various organs like
the breast and implicated in numerous cellular processes like
differentiation, migration, proliferation, etc. During lactation,
it coordinates maternal and neonatal calcium metabolism.
However, in a diseased setting, where there is rising evidence
of the CaSR acting as an oncogene in breast cancer, it is said
to facilitate a vicious cycle of osteolysis and tumor growth
affecting the pathophysiology of bone metastases. Breast cancer
is the prime cause of cancer mortality in women and although
we have come a long way in diagnosis, treatment, and disease
management, metastatic disease remains a major challenge.
Current therapies are bone-targeted, and we present a case where
CaSR antagonists can be an alternate strategy or further improve
the standard-of-care. The CaSR may sit in a cascade of complex
signaling events and it would be worth investigating if CaSR
based agents can prevent or delay bone destruction, even though
more work is required to elucidate the intricacies of its role and
for producing better targeted drugs.
AUTHOR CONTRIBUTIONS
SD and RM conceived the idea for the review. SD wrote
the manuscript under the guidance of RM. PC, SK, and MB
contributed to substantial inputs which helped structure the
review and frame the concepts.
FUNDING
SD was funded from the Marie Sklodowska-Curie Actions of the
European Union’s Horizon 2020 program under grant agreement
no. 675228 as part of the CaSR Biomedicine Network.
ACKNOWLEDGMENTS
We would especially like to thank the French Society for
Mineralized Tissue Biology (SFBTM), Foundation Arthritis,
and Association for Research and Development of Anticancer
Chemotherapy (ARDCA) for supporting the project.
REFERENCES
1. Nemeth EF. Misconceptions about calcimimetics. Ann N Y Acad Sci. (2006)
1068:471–6. doi: 10.1196/annals.1346.044
2. McLean FC. Unsolved problems of parathyroid physiology. In: Greep RO,
Talmage RV, editors. The Parathyroids. Springfield, IL: Charles C. Thomas
(1961). p. 7–18.
3. López-Barneo J, Armstrong CM. Depolarizing response of rat
parathyroid cells to divalent cations. J Gen Physiol. (1983)
82:269–94. doi: 10.1085/jgp.82.2.269
4. Shoback DM, Chen TH. Injection of poly(A)+ RNA from bovine
parathyroid tissue into Xenopus oocytes confers sensitivity to extracellular
calcium. J. Bone Miner. Res. (1991) 6:S135.
5. Racke FK, Dubyak GR, Nemeth EF. Functional expression of the parathyroid
cell calcium receptor in Xenopus oocytes. J. Bone Miner. Res. (1991)
6:S118.
6. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al.
Cloning and characterization of an extracellular Ca2+-sensing receptor from
bovine parathyroid. Nature. (1993) 366:575–80. doi: 10.1038/366575a0
7. Pollak MR, Brown EM, Chou Y-HW, Hebert SC, Marx SJ, Stelnmann B,
et al. Mutations in the human Ca2+-sensing receptor gene cause familial
hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell.
(1993) 75:1297–303. doi: 10.1016/0092-8674(93)90617-Y
8. Zhang C, Zhang T, Zou J, Miller CL, Gorkhali R, Yang J-Y, et al. Structural
basis for regulation of human calcium-sensing receptor by magnesium
ions and an unexpected tryptophan derivative co-agonist. Sci Adv. (2016)
2:e1600241. doi: 10.1126/sciadv.1600241
9. Chakravarti B, Chattopadhyay N, Brown EM. Signaling through the
extracellular Calcium-Sensing Receptor (CaSR). In: Shahidul IM, editors,
Calcium Signaling. Dordrecht: Springer (2012). p. 103–42.
10. Nemeth EF. Regulation of cytosolic calcium by extracellular divalent
cations in C-cells and parathyroid cells. Cell Calcium. (1990) 11:323–
7. doi: 10.1016/0143-4160(90)90033-Q
11. Quinn SJ, Ye CP, Diaz R, Kifor O, Bai M, Vassilev P, et al. The Ca2+-
sensing receptor: a target for polyamines. Am J Physiol. (1997) 273:C1315–
23. doi: 10.1152/ajpcell.1997.273.4.C1315
12. Brown EM, Katz C, Butters R, Kifor O. Polyarginine, polylysine, and
protamine mimic the effects of high extracellular calcium concentrations
Frontiers in Oncology | www.frontiersin.org 8 February 2020 | Volume 10 | Article 69
Das et al. CaSR and Calcilytics in Breast Cancer Metastases
on dispersed bovine parathyroid cells. J Bone Miner Res. (1991) 6:1217–
25. doi: 10.1002/jbmr.5650061112
13. Ye C, Ho-Pao CL, Kanazirska M, Quinn S, Rogers K, Seidman
CE, et al. Amyloid-beta proteins activate Ca(2+)-permeable channels
through calcium-sensing receptors. J Neurosci Res. (1997) 47:547–54.
doi: 10.1002/(SICI)1097-4547(19970301)47:5<547::AID-JNR10>3.0.CO;2-V
14. Brown EM, Butters R, Katz C, Kifor O. Neomycin mimics the effects
of high extracellular calcium concentrations on parathyroid function
in dispersed bovine parathyroid cells. Endocrinology. (1991) 128:3047–
54. doi: 10.1210/endo-128-6-3047
15. Brown E, Enyedi P, LeBoff M, Rotberg J, Preston J, Chen C.
High extracellular Ca2+ and Mg2+ stimulate accumulation of
inositol phosphates in bovine parathyroid cells. FEBS Lett. (1987)
218:113–8. doi: 10.1016/0014-5793(87)81029-3
16. Wettschureck N, Lee E, Libutti SK, Offermanns S, Robey PG, Spiegel
AM. Parathyroid-specific double knockout of Gq and G11 alpha-
subunits leads to a phenotype resembling germline knockout of the
extracellular Ca2+ -sensing receptor. Mol Endocrinol. (2007) 21:274–
80. doi: 10.1210/me.2006-0110
17. Hannan FM, Babinsky VN, Thakker RV. Disorders of the
calcium-sensing receptor and partner proteins: insights into the
molecular basis of calcium homeostasis. J Mol Endocrinol. (2016)
57:R127–42. doi: 10.1530/JME-16-0124
18. Brennan T, Rybchyn M, Green W, Atwa S, Conigrave A, Mason R.
Osteoblasts play key roles in the mechanisms of action of strontium ranelate.
Br J Pharmacol. (2009) 157:1291–300. doi: 10.1111/j.1476-5381.2009.00305.x
19. Rybchyn MS, Slater M, Conigrave AD, Mason RS. An Akt-dependent
increase in canonicalWnt signaling and a decrease in sclerostin protein levels
are involved in strontium ranelate-induced osteogenic effects in human
osteoblasts. J Biol Chem. (2011) 286:23771–9. doi: 10.1074/jbc.M111.251116
20. Worzfeld T, Wettschureck N, Offermanns S. G12/G13-mediated signalling
in mammalian physiology and disease. Trends Pharmacol Sci. (2008) 29:582–
9. doi: 10.1016/j.tips.2008.08.002
21. Ward DT, Riccardi D. New concepts in calcium-sensing
receptor pharmacology and signalling. Br J Pharmacol. (2012)
165:35–48. doi: 10.1111/j.1476-5381.2011.01511.x
22. Brennan SC, Thiem U, Roth S, Aggarwal A, Fetahu ISh, Tennakoon S,
et al. Calcium sensing receptor signalling in physiology and cancer. Biochim
Biophys Acta. (2013) 1833:1732–44. doi: 10.1016/j.bbamcr.2012.12.011
23. Mamillapalli R, Wysolmerski J. The calcium-sensing receptor couples to Gαs
and regulates PTHrP and ACTH secretion in pituitary cells. J Endocrinol.
(2010) 204:287–97. doi: 10.1677/JOE-09-0183
24. Brennan SC, Wilkinson WJ, Tseng H-E, Finney B, Monk B, Dibble H,
et al. The extracellular calcium-sensing receptor regulates human fetal lung
development via CFTR. Sci Rep. (2016) 6. doi: 10.1038/srep21975
25. Conigrave AD, Ward DT. Calcium-sensing receptor (CaSR):
pharmacological properties and signaling pathways. Best Pract Res
Clin Endocrinol Metab. (2013) 27:315–31. doi: 10.1016/j.beem.2013.
05.010
26. Thomsen ARB, Smajilovic S, Bräuner-Osborne H. Novel strategies in drug
discovery of the calcium-sensing receptor based on biased signaling. Curr
Drug Targets. (2012) 13:1324–35. doi: 10.2174/138945012802429642
27. Leach K, Conigrave AD, Sexton PM, Christopoulos A. Towards tissue-
specific pharmacology: insights from the calcium-sensing receptor as a
paradigm for GPCR (patho)physiological bias. Trends Pharmacol Sci. (2015)
36:215–25. doi: 10.1016/j.tips.2015.02.004
28. Hofer AM, Brown EM. Calcium: extracellular calcium sensing and signalling.
Nat Rev Mol Cell Biol. (2003) 4:530–8. doi: 10.1038/nrm1154
29. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, et al.
Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor
gene mutation. Nat Genet. (1994) 8:303–7. doi: 10.1038/ng1194-303
30. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y,
Okazaki R, et al. Association between activating mutations of
calcium-sensing receptor and Bartter’s syndrome. Lancet. (2002)
360:692–4. doi: 10.1016/S0140-6736(02)09842-2
31. Alfadda TI, Saleh AMA, Houillier P, Geibel JP. Calcium-
sensing receptor 20 years later. Am J Physiol Cell Physiol. (2014)
307:C221–31. doi: 10.1152/ajpcell.00139.2014
32. Aida K, Koishi S, Tawata M, Onaya T. Molecular cloning of a putative
Ca(2+)-sensing receptor cDNA from human kidney. Biochem Biophys Res
Commun. (1995) 214:524–9. doi: 10.1006/bbrc.1995.2318
33. Ray JM, Squires PE, Curtis SB, Meloche MR, Buchan AM. Expression of
the calcium-sensing receptor on human antral gastrin cells in culture. J Clin
Invest. (1997) 99:2328–33. doi: 10.1172/JCI119413
34. Chattopadhyay N, Cheng I, Rogers K, Riccardi D, Hall A,
Diaz R, et al. Identification and localization of extracellular
Ca(2+)-sensing receptor in rat intestine. Am J Physiol. (1998)
274:G122–30. doi: 10.1152/ajpgi.1998.274.1.G122
35. Bikle DD, Ratnam A, Mauro T, Harris J, Pillai S. Changes in calcium
responsiveness and handling during keratinocyte differentiation.
Potential role of the calcium receptor. J Clin Invest. (1996)
97:1085–93. doi: 10.1172/JCI118501
36. Tu C-L, Chang W, Xie Z, Bikle DD. Inactivation of the calcium sensing
receptor inhibits E-cadherin-mediated cell-cell adhesion and calcium-
induced differentiation in human epidermal keratinocytes. J Biol Chem.
(2008) 283:3519–28. doi: 10.1074/jbc.M708318200
37. Ruat M, Molliver ME, Snowman AM, Snyder SH. Calcium sensing receptor:
molecular cloning in rat and localization to nerve terminals. Proc Natl Acad
Sci USA. (1995) 92:3161–5. doi: 10.1073/pnas.92.8.3161
38. Canaff L, Petit JL, Kisiel M, Watson PH, Gascon-Barré M, Hendy GN.
Extracellular calcium-sensing receptor is expressed in rat hepatocytes.
coupling to intracellular calcium mobilization and stimulation of
bile flow. J Biol Chem. (2001) 276:4070–9. doi: 10.1074/jbc.M009
317200
39. Tfelt-Hansen J, Hansen JL, Smajilovic S, Terwilliger EF, Haunso S, Sheikh
SP. Calcium receptor is functionally expressed in rat neonatal ventricular
cardiomyocytes. Am J Physiol Heart Circ Physiol. (2006) 290:H1165–
71. doi: 10.1152/ajpheart.00821.2005
40. Cheng I, Klingensmith ME, Chattopadhyay N, Kifor O, Butters RR, Soybel
DI, et al. Identification and localization of the extracellular calcium-
sensing receptor in human breast. J Clin Endocrinol Metab. (1998) 83:703–
7. doi: 10.1210/jcem.83.2.4558
41. VanHouten J, Dann P, McGeoch G, Brown EM, Krapcho K, Neville
M, et al. The calcium-sensing receptor regulates mammary gland
parathyroid hormone–related protein production and calcium
transport. J Clin Invest. (2004) 113:598–608. doi: 10.1172/JCI20041
8776
42. VanHouten JN, Neville MC, Wysolmerski JJ. The calcium-sensing receptor
regulates plasma membrane calcium adenosine triphosphatase isoform
2 activity in mammary epithelial cells: a mechanism for calcium-
regulated calcium transport into milk. Endocrinology. (2007) 148:5943–
54. doi: 10.1210/en.2007-0850
43. Kim W, Wysolmerski JJ. Calcium-sensing receptor in breast physiology
and cancer. Front Physiol. (2016) 7:440. doi: 10.3389/fphys.2016.
00440
44. Mamillapalli R, VanHouten J, Dann P, Bikle D, Chang W, Brown
E, et al. Mammary-specific ablation of the calcium-sensing receptor
during lactation alters maternal calcium metabolism, milk calcium
transport, and neonatal calcium accrual. Endocrinology. (2013) 154:3031–
42. doi: 10.1210/en.2012-2195
45. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ,
et al. Humoral hypercalcemia of cancer. Identification of a novel
parathyroid hormone-like peptide. N Engl J Med. (1988) 319:556–
63. doi: 10.1056/NEJM198809013190906
46. Hiremath M, Wysolmerski J. Role of PTHrP in mammary gland
development and breast cancer. Clin Rev Bone Miner Metab. (2014) 12:178–
89. doi: 10.1007/s12018-014-9170-9
47. Jüppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E,
Richards J, et al. A G protein-linked receptor for parathyroid hormone
and parathyroid hormone-related peptide. Science. (1991) 254:1024–
6. doi: 10.1126/science.1658941
48. Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR,
Brown EM. Extracellular calcium-sensing receptor expression and its
potential role in regulating parathyroid hormone-related peptide secretion
in human breast cancer cell lines. Endocrinology. (2000) 141:4357–
64. doi: 10.1210/endo.141.12.7849
Frontiers in Oncology | www.frontiersin.org 9 February 2020 | Volume 10 | Article 69
Das et al. CaSR and Calcilytics in Breast Cancer Metastases
49. Casalà C, Gil-Guiñón E, Ordóñez JL, Miguel-Queralt S, Rodríguez E,
Galván P, et al. The calcium-sensing receptor is silenced by genetic and
epigenetic mechanisms in unfavorable neuroblastomas and its reactivation
induces ERK1/2-dependent apoptosis. Carcinogenesis. (2013) 34:268–
76. doi: 10.1093/carcin/bgs338
50. Haven CJ, van Puijenbroek M, Karperien M, Fleuren G-J, Morreau H.
Differential expression of the calcium sensing receptor and combined loss
of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol. (2004)
202:86–94. doi: 10.1002/path.1489
51. Fetahu IS, Höbaus J, Aggarwal A, Hummel DM, Tennakoon S, Mesteri I,
et al. Calcium-sensing receptor silencing in colorectal cancer is associated
with promoter hypermethylation and loss of acetylation on histone 3. Int J
Cancer. (2014) 135:2014–23. doi: 10.1002/ijc.28856
52. Hobson SA, Wright J, Lee F, McNeil SE, Bilderback T, Rodland
KD. Activation of the MAP kinase cascade by exogenous
calcium-sensing receptor. Mol Cell Endocrinol. (2003) 200:189–
98. doi: 10.1016/S0303-7207(01)00749-3
53. Feng J, Xu X, Li B, Brown E, Farris AB, Sun S-Y, et al. Prostate cancer
metastatic to bone has higher expression of the calcium-sensing receptor
(CaSR) than primary prostate cancer. Receptors Clin Investig. (2014)
1:e270. doi: 10.14800/rci.270
54. Tfelt-Hansen J, Schwarz P, Terwilliger EF, Brown EM, Chattopadhyay N.
Calcium-sensing receptor induces messenger ribonucleic acid of human
securin, pituitary tumor transforming gene, in rat testicular cancer.
Endocrinology. (2003) 144:5188–93. doi: 10.1210/en.2003-0520
55. Campos-Verdes LM, Costa-Silva DR, Silva-Sampaio JP da, Barros-Oliveira
M da C, Escórcio-Dourado CS, Martins LM, et al. Review of polymorphism
of the calcium-sensing receptor gene and breast cancer risk. Cancer Invest.
(2018) 36:1–7. doi: 10.1080/07357907.2018.1430817
56. Yao S, Haddad SA, Hu Q, Liu S, Lunetta KL, Ruiz-Narvaez EA, et al.
Genetic variations in vitamin D-related pathways and breast cancer risk in
African American women in the AMBER consortium. Int J Cancer. (2016)
138:2118–26. doi: 10.1002/ijc.29954
57. Li X, Kong X, Jiang L, Ma T, Yan S, Yuan C, et al. A genetic polymorphism
(rs17251221) in the calcium-sensing receptor is associated with breast
cancer susceptibility and prognosis. Cell Physiol Biochem. (2014) 33:165–
72. doi: 10.1159/000356659
58. Yan S, Yuan C, Yang Q, Li X, Yang N, Liu X, et al. A genetic polymorphism
(rs17251221) in the calcium-sensing receptor is associated with ovarian
cancer susceptibility.Oncol Rep. (2015) 34:2151–5. doi: 10.3892/or.2015.4179
59. Wang L, Widatalla SE, Whalen DS, Ochieng J, Sakwe AM. Association
of calcium sensing receptor polymorphisms at rs1801725 with
circulating calcium in breast cancer patients. BMC Cancer. (2017)
17:511. doi: 10.1186/s12885-017-3502-3
60. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S. BRCA1 suppresses the
expression of survivin and promotes sensitivity to paclitaxel through the
calcium sensing receptor (CaSR) in human breast cancer cells. Cell Calcium.
(2011) 49:79–88. doi: 10.1016/j.ceca.2011.01.003
61. Mamillapalli R, VanHouten J, Zawalich W, Wysolmerski J. Switching of
G-protein usage by the calcium-sensing receptor reverses its effect on
parathyroid hormone-related protein secretion in normal versus malignant
breast cells. J Biol Chem. (2008) 283:24435–47. doi: 10.1074/jbc.M801738200
62. Chilco PJ, Leopold V, Zajac JD. Differential regulation of the parathyroid
hormone-related protein gene P1 and P3 promoters by cAMP. Mol Cell
Endocrinol. (1998) 138:173–84. doi: 10.1016/S0303-7207(97)00239-6
63. Takagaki K, Takashima T, Onoda N, Tezuka K, Noda E, Kawajiri H, et al.
Parathyroid hormone-related protein expression, in combination with nodal
status, predicts bone metastasis and prognosis of breast cancer patients. Exp
Ther Med. (2012) 3:963–8. doi: 10.3892/etm.2012.521
64. Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PFM,
Spillane JB, et al. Parathyroid hormone-related protein localization in
breast cancers predict improved prognosis. Cancer Res. (2006) 66:2250–
6. doi: 10.1158/0008-5472.CAN-05-2814
65. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks
E, et al. Genome-wide association analysis identifies three new breast cancer
susceptibility loci. Nat Genet. (2012) 44:312–8. doi: 10.1038/ng.1049
66. KimW, Takyar FM, Swan K, Jeong J, VanHouten J, Sullivan C, et al. Calcium-
sensing receptor promotes breast cancer by stimulating intracrine actions
of parathyroid hormone–related protein. Cancer Res. (2016) 76:5348–
60. doi: 10.1158/0008-5472.CAN-15-2614
67. Yang Y, Wang B. PTH1R-CaSR cross talk: new treatment options
for breast cancer osteolytic bone metastases. Int J Endocrinol. (2018)
2018:8. doi: 10.1155/2018/7120979
68. Colloton M, Shatzen E, Wiemann B, Starnes C, Scully S, Henley C, et al.
Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice
H-500 Leydig cell or C26-DCT colon tumors. Eur J Pharmacol. (2013)
712:8–15. doi: 10.1016/j.ejphar.2013.04.013
69. Paget S. The distribution of secondary growths in cancer of the breast. 1889.
Cancer Metastasis Rev. (1989) 8:98–101.
70. Guise T. Examining the metastatic niche: targeting the
microenvironment. Semin Oncol. (2010) 37(Suppl. 2):S2–
14. doi: 10.1053/j.seminoncol.2010.10.007
71. Saidak Z, Boudot C, Abdoune R, Petit L, Brazier M, Mentaverri R, et al.
Extracellular calcium promotes the migration of breast cancer cells through
the activation of the calcium sensing receptor. Exp Cell Res. (2009) 315:2072–
80. doi: 10.1016/j.yexcr.2009.03.003
72. Boudot C, Hénaut L, Thiem U, Geraci S, Galante M, Saldanha P, et al.
Overexpression of a functional calcium-sensing receptor dramatically
increases osteolytic potential of MDA-MB-231 cells in a mouse model
of bone metastasis through epiregulin-mediated osteoprotegerin
downregulation.Oncotarget. (2017) 8:56460. doi: 10.18632/oncotarget.16999
73. Tharmalingam S, Daulat AM, Antflick JE, Ahmed SM, Nemeth EF, Angers
S, et al. Calcium-sensing receptor modulates cell adhesion and migration via
integrins. J Biol Chem. (2011) 286:40922–33. doi: 10.1074/jbc.M111.265454
74. Saidak Z, Mentaverri R, Brown EM. The role of the calcium-sensing receptor
in the development and progression of cancer. Endocr Rev. (2009) 30:178–
95. doi: 10.1210/er.2008-0041
75. Lam BS, Cunningham C, Adams GB. Pharmacologic modulation
of the calcium-sensing receptor enhances hematopoietic stem cell
lodgment in the adult bone marrow. Blood. (2011) 117:1167–
75. doi: 10.1182/blood-2010-05-286294
76. Morgan MP, Cooke MM, McCarthy GM. Microcalcifications associated
with breast cancer: an epiphenomenon or biologically significant feature
of selected tumors? J Mammary Gland Biol Neoplasia. (2005) 10:181–
7. doi: 10.1007/s10911-005-5400-6
77. Rominger MB, Steinmetz C, Westerman R, Ramaswamy A, Albert U-
S. microcalcification-associated breast cancer: presentation, successful first
excision, long-term recurrence and survival rate. Breast Care. (2015) 10:380–
5. doi: 10.1159/000440794
78. Bellahcène A, Castronovo V. Expression of bone matrix proteins in human
breast cancer: potential roles in microcalcification formation and in the
genesis of bone metastases. Bull Cancer. (1997) 84:17–24.
79. Wilkinson L, Thomas V, Sharma N. Microcalcification on mammography:
approaches to interpretation and biopsy. Br J Radiol. (2019) 90:2016094.
doi: 10.1259/bjr.20160594
80. Cox RF, Jenkinson A, Pohl K, O’Brien FJ, Morgan MP. Osteomimicry
of mammary adenocarcinoma cells in vitro; increased expression of bone
matrix proteins and proliferation within a 3D collagen environment. PLoS
ONE. (2012) 7:e41679. doi: 10.1371/journal.pone.0041679
81. Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW,
et al. Induction of epithelial-mesenchymal transition (EMT) in breast
cancer cells is calcium signal dependent. Oncogene. (2014) 33:2307–
16. doi: 10.1038/onc.2013.187
82. El Hiani Y, Ahidouch A, Lehen’kyi V, Hague F, Gouilleux F, Mentaverri
R, et al. Extracellular signal-regulated kinases 1 and 2 and TRPC1
channels are required for calcium-sensing receptor-stimulated MCF-7
breast cancer cell proliferation. Cell Physiol Biochem. (2009) 23:335–
46. doi: 10.1159/000218179
83. El Hiani Y, Lehen’kyi V, Ouadid-Ahidouch H, Ahidouch A. Activation
of the calcium-sensing receptor by high calcium induced breast
cancer cell proliferation and TRPC1 cation channel over-expression
potentially through EGFR pathways. Arch Biochem Biophys. (2009)
486:58–63. doi: 10.1016/j.abb.2009.03.010
84. Aggarwal A, Prinz-Wohlgenannt M, Gröschel C, Tennakoon S,
Meshcheryakova A, ChangW, et al. The calcium-sensing receptor suppresses
epithelial-to-mesenchymal transition and stem cell- like phenotype in
Frontiers in Oncology | www.frontiersin.org 10 February 2020 | Volume 10 | Article 69
Das et al. CaSR and Calcilytics in Breast Cancer Metastases
the colon. Molecular Cancer. (2015) 14:61. doi: 10.1186/s12943-015-
0330-4
85. Singh N, Aslam MN, Varani J, Chakrabarty S. Induction of calcium sensing
receptor in human colon cancer cells by calcium, vitamin D and aquamin:
promotion of a more differentiated, less malignant and indolent phenotype.
Mol Carcinogen. (2015) 54:543–53. doi: 10.1002/mc.22123
86. Wen L, Sun L, Xi Y, Chen X, Xing Y, Sun W, et al. Expression
of calcium sensing receptor and E-cadherin correlated with
survival of lung adenocarcinoma. Thoracic Cancer. (2015)
6:754–60. doi: 10.1111/1759-7714.12255
87. Hua H, Zhang H, Kong Q, Jiang Y. Mechanisms for estrogen
receptor expression in human cancer. Exp Hematol Oncol. (2018)
7:24. doi: 10.1186/s40164-018-0116-7
88. Journé F, Dumon J-C, Kheddoumi N, Fox J, Laios I, Leclercq G, et al.
Extracellular calcium downregulates estrogen receptor alpha and increases
its transcriptional activity through calcium-sensing receptor in breast cancer
cells. Bone. (2004) 35:479–88. doi: 10.1016/j.bone.2004.03.021
89. Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel
S, et al. The calcium sensing receptor is directly involved in
both osteoclast differentiation and apoptosis. FASEB J. (2006)
20:2562–4. doi: 10.1096/fj.06-6304fje
90. Nemeth EF. Anabolic therapy for osteoporosis: calcilytics. IBMS BoneKEy.
(2008) 5:196–208. doi: 10.1138/20080318
91. Nemeth EF, Delmar EG, Heaton WL, Miller MA, Lambert LD, Conklin RL,
et al. Calcilytic compounds: potent and selective Ca2+receptor antagonists
that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther.
(2001) 299:323−31.
92. Nemeth EF, Van Wagenen BC, Balandrin MF. Chapter one
- discovery and development of calcimimetic and calcilytic
compounds. In: Witty DR, Cox B, editors. Progress in Medicinal
Chemistry. Elsevier (2018). p. 1–86. doi: 10.1016/bs.pmch.2017.
12.001
93. Nemeth EF, Goodman WG. Calcimimetic and calcilytic drugs:
feats, flops, and futures. Calcif Tissue Int. (2016) 98:341–
58. doi: 10.1007/s00223-015-0052-z
94. Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, et al.
Physiological changes in extracellular calcium concentration directly control
osteoblast function in the absence of calciotropic hormones. Proc Natl Acad
Sci USA. (2004) 101:5140–5. doi: 10.1073/pnas.0306141101
95. Goltzman D, Hendy GN. The calcium-sensing receptor in bone—
mechanistic and therapeutic insights. Nat Rev Endocrinol. (2015) 11:298–
307. doi: 10.1038/nrendo.2015.30
96. Santa Maria C, Cheng Z, Li A, Wang J, Shoback D, Tu C-L,
et al. Interplay between CaSR and PTH1R signaling in skeletal
development and osteoanabolism. Semin Cell Dev Biol. (2016)
49:11–23. doi: 10.1016/j.semcdb.2015.12.004
97. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al.
Antagonizing the parathyroid calcium receptor stimulates parathyroid
hormone secretion and bone formation in osteopenic rats. J Clin Invest.
(2000) 105:1595–604. doi: 10.1172/JCI9038
98. Quinn SJ, Bai M, Brown EM. pH sensing by the calcium-sensing
receptor. J Biol Chem. (2004) 279:37241–9. doi: 10.1074/jbc.M4045
20200
99. Joeckel E, Haber T, Prawitt D, Junker K, Hampel C, Thüroff JW, et al.
High calcium concentration in bones promotes bone metastasis in renal cell
carcinomas expressing calcium-sensing receptor. Molecular Cancer. (2014)
13:42. doi: 10.1186/1476-4598-13-42
100. Frees S, Breuksch I, Haber T, Bauer H-K, Chavez-Munoz C, Raven
P, et al. Calcium-sensing receptor (CaSR) promotes development of
bone metastasis in renal cell carcinoma. Oncotarget. (2018) 9:15766–
79. doi: 10.18632/oncotarget.24607
101. Nielsen PK, Rasmussen AK, Butters R, Feldt-Rasmussen U, Bendtzen K,
Diaz R, et al. Inhibition of PTH secretion by interleukin-1 beta in bovine
parathyroid glands in vitro is associated with an up-regulation of the
calcium-sensing receptor mRNA. Biochem Biophys Res Commun. (1997)
238:880–5. doi: 10.1006/bbrc.1997.7207
102. Hernández-Bedolla MA, Carretero-Ortega J, Valadez-Sánchez M, Vázquez-
Prado J, Reyes-Cruz G. Chemotactic and proangiogenic role of calcium
sensing receptor is linked to secretion of multiple cytokines and growth
factors in breast cancer MDA-MB-231 cells. Biochim Biophys Acta. (2015)
1853:166–82. doi: 10.1016/j.bbamcr.2014.10.011
103. Hernández-Bedolla MA, González-Domínguez E, Zavala-Barrera
C, Gutiérrez-López TY, Hidalgo-Moyle JJ, Vázquez-Prado J, et al.
Calcium-sensing-receptor (CaSR) controls IL-6 secretion in metastatic
breast cancer MDA-MB-231 cells by a dual mechanism revealed by
agonist and inverse-agonist modulators. Mol Cell Endocrinol. (2016)
436:159–68. doi: 10.1016/j.mce.2016.07.038
104. Xie R, Xu J, Xiao Y, Wu J, Wan H, Tang B, et al. Calcium
promotes human gastric cancer via a novel coupling of
calcium-sensing receptor and TRPV4 channel. Cancer Res. (2017)
77:6499–512. doi: 10.1158/0008-5472.CAN-17-0360
105. Xie R, Tuo B, Yang S, Chen X-Q, Xu J. Calcium-sensing receptor bridges
calcium and telomerase reverse transcriptase in gastric cancers via Akt. Clin
Transl Oncol. (2019). doi: 10.1007/s12094-019-02226-4
106. Zhang Z-L, Li Z-R, Li J-S, Wang S-R. Calcium-sensing receptor antagonist
NPS-2143 suppresses proliferation and invasion of gastric cancer cells.
Cancer Gene Ther. (2019). doi: 10.1038/s41417-019-0128-4
107. Yamamura A, Nayeem MJ, Sato M. Calcilytics inhibit the proliferation and
migration of human prostate cancer PC-3 cells. J Pharmacol Sci. (2019)
139:254–7. doi: 10.1016/j.jphs.2019.01.008
108. Sigvaldason H, Obayan A, von Kuster K, Pathak KA. Hypercalcemia in
metastatic breast cancer unrelated to skeletal metastasis. CMAJ. (2016)
188:E91–4. doi: 10.1503/cmaj.150638
109. Horwitz MJ, Tedesco MB, Sereika SM, Prebehala L, Gundberg CM, Hollis
BW, et al. A 7-day continuous infusion of PTH or PTHrP suppresses
bone formation and uncouples bone turnover. J Bone Miner Res. (2011)
26:2287–97. doi: 10.1002/jbmr.415
110. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY,
et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral
density in postmenopausal women with osteoporosis. N Engl J Med. (2001)
344:1434–41. doi: 10.3171/foc.2001.11.2.8
111. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect
of abaloparatide vs. placebo on new vertebral fractures in postmenopausal
women with osteoporosis: a randomized clinical trial. JAMA. (2016)
316:722–33. doi: 10.1001/jama.2016.11136
112. Swami S, Johnson J, Bettinson LA, Kimura T, Zhu H, Albertelli MA, et al.
Prevention of breast cancer skeletal metastases with parathyroid hormone.
JCI Insight. (2017) 2:90874. doi: 10.1172/jci.insight.90874
113. Sousa S, Clézardin P. Bone-targeted therapies in cancer-induced bone
disease. Calcif Tissue Int. (2018) 102:227–50. doi: 10.1007/s00223-017-
0353-5
114. Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and
benefits of bisphosphonate therapies. J Cell Biochem. (2016) 117:20–
8. doi: 10.1002/jcb.25266
115. Maurizi A, Rucci N. The osteoclast in bone metastasis: player and target.
Cancers. (2018) 10:218. doi: 10.3390/cancers10070218
116. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski
M, et al. Zoledronic acid versus placebo in the treatment of skeletal
metastases in patients with lung cancer and other solid tumors: a phase
III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer
and Other Solid Tumors Study Group. J Clin Oncol. (2003) 21:3150–
7. doi: 10.1200/JCO.2003.04.105
117. Body J-J, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R,
et al. Hypocalcaemia in patients with metastatic bone disease treated with
denosumab. Eur J Cancer. (2015) 51:1812–21. doi: 10.1016/j.ejca.2015.05.016
118. Lüftner D, Niepel D, Steger GG. Therapeutic approaches for protecting
bone health in patients with breast cancer. Breast. (2018) 37:28–
35. doi: 10.1016/j.breast.2017.10.007
119. Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J
Bone Oncol. (2014) 3:25–35. doi: 10.1016/j.jbo.2013.12.001
120. Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, et al.
Predictive value of bone resorption and formationmarkers in cancer patients
with bone metastases receiving the bisphosphonate zoledronic acid. J Clin
Oncol. (2016) 23:4925–35. doi: 10.1200/JCO.2005.06.091
121. Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, et al. The
cathepsin K inhibitor odanacatib suppresses bone resorption in women with
Frontiers in Oncology | www.frontiersin.org 11 February 2020 | Volume 10 | Article 69
Das et al. CaSR and Calcilytics in Breast Cancer Metastases
breast cancer and established bone metastases: results of a 4-week, double-
blind, randomized, controlled trial. Clin Breast Cancer. (2010) 10:452–
8. doi: 10.3816/CBC.2010.n.059
122. Yang JC, Bai L, Yap S, Gao AC, Kung H-J, Evans CP. Effect
of the specific Src family kinase inhibitor saracatinib on
osteolytic lesions using the PC-3 bone model. Mol Cancer
Ther. (2010) 9:1629–37. doi: 10.1158/1535-7163.MCT-09-
1058
123. Carter RZ, Micocci KC, Natoli A, Redvers RP, Paquet-Fifield S, Martin
ACBM, et al. Tumour but not stromal expression of β3 integrin is
essential, and is required early, for spontaneous dissemination of bone-
metastatic breast cancer. J Pathol. (2015) 235:760–72. doi: 10.1002/path.
4490
124. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-
Fox M, Gaddy D, et al. Inhibitory effects of osteoblasts and
increased bone formation on myeloma in novel culture systems
and a myelomatous mouse model. Haematologica. (2006)
91:192–9.
125. Adamik J, Galson DL, Roodman GD. Osteoblast suppression
in multiple myeloma bone disease. J Bone Oncol. (2018)
13:62–70. doi: 10.1016/j.jbo.2018.09.001
126. Krawetz R, Wu YE, Rancourt DE, Matyas J. Osteoblasts suppress high bone
turnover caused by osteolytic breast cancer in vitro. Exp Cell Res. (2009)
315:2333–42. doi: 10.1016/j.yexcr.2009.04.026
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Das, Clézardin, Kamel, Brazier and Mentaverri. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Oncology | www.frontiersin.org 12 February 2020 | Volume 10 | Article 69
